Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.
about
Pharmacogenetics and anaesthesia: the value of genetic profilingClopidogrel: the data, the experience, and the controversies.Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapyImpact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese populationSystematic reviews and meta-analyses for more profitable strategies in peripheral artery diseaseRoutine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommendedTailored antiplatelet therapy and clinical adverse outcomes.Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndromeAnti-platelet therapy: ADP receptor antagonists.Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease.The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count.Circulating primers enhance platelet function and induce resistance to antiplatelet therapy.Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Personalised medicine: not just in our genes.Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.A comparison of the metabolism of clopidogrel and prasugrel.Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?Antiplatelet therapy in acute coronary syndromes.Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.Biomarkers in acute coronary artery disease.Platelet function testing in patients with acute coronary syndrome.Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?Gender and anti-thrombotic therapy: from biology to clinical implications.Pharmacogenetics of antiplatelet therapy.Genetic determinations of variable responsiveness to clopidogrel and implications for neurointerventional procedures.The P2Y(12) receptor as a target of antithrombotic drugsThe pharmacodynamics of antiplatelet compounds in thrombosis treatment.New directions for pharmacotherapy in the treatment of acute coronary syndrome.High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.
P2860
Q26859221-D8280505-7F13-4BFC-B99C-B05DEB650E31Q30573045-EF28DBB7-A4B5-4454-A583-4FA3153363D9Q30840104-4B1998E3-CCD9-41D8-A8AB-DA4CDC8976E4Q33704998-1BC0A349-6FB5-487D-BBD2-9C99DA130C65Q33791290-700C55A0-2465-4E31-B29A-CCA830B4BBF2Q33982372-A92AC3F5-2DF8-4676-9379-04D2B7BA2B89Q34035039-5F645F1A-16DB-4158-BE77-CE752645A76BQ34314265-F39A10F2-7D25-442C-B16D-52F0A2663986Q34576281-D515B899-5592-4B27-87EA-7B2FAC101DB2Q34990721-613069D1-3756-4AEC-9B41-5E92B402F637Q35032042-B3BDB4E3-4A9E-478C-BD57-A976A7366349Q35250401-0D871E0F-1003-46F3-A972-E26755A8499FQ35278165-954F099A-7E27-4183-87E8-AC721E7D0BC2Q35373683-5C21AFAD-46B3-460F-B844-FDFBCDD5759CQ35869541-9EC0843E-CB0B-46F0-A215-F42C27E1C3A1Q35925903-E2BEC418-09D0-4DC6-A880-CF934B66BE1FQ36140286-F8DFE0E0-E348-478D-A1F5-C3039A291F48Q36160606-7B4C3E3E-0826-4BD0-8E7E-90CDA3CA1C13Q36396620-9C885737-7D22-4DBA-B5AB-CBAB598F0DEBQ36599251-B4E982A9-1B31-4D1A-92F8-33A44D5A32BFQ37429557-F180EF49-D2D6-40CC-84D7-4039D9041B3EQ37497555-80B8C9E0-97A3-4223-8EF4-FA2E39003AE4Q37788682-45BAE224-C7AA-43C8-9AC9-E522E86EA62EQ37924323-179D324E-BD2E-4EDC-A8AB-3714CDDE2BD2Q37965609-78786A19-97B4-421D-904E-FC49F4F8263AQ38008466-5E0A20CC-0DE1-442D-B9D3-019C98C05B37Q38012079-830D9BDA-F62E-4279-88AF-B3E729BB9B85Q38018674-62A073AB-C2BD-492F-A745-2B3FBE7B9B69Q38059154-EF5547B4-FA59-46A8-BB04-0A8E53359377Q38080466-5922885B-C90B-40C7-BB6B-E17D9AE1A7FAQ38106616-F4BE72CB-06AF-4704-BD20-5D5594F2B8EEQ38153606-F499065A-FC46-42AF-8421-578EE0212D85Q38182428-02C81C91-1A8B-4FE2-8DC4-D61FB84BBBD7Q38199010-BA10C81D-F74F-4E53-8C37-59646AD3B06AQ38246009-96185734-3297-42A2-B86A-5BB5BBC5B9B6Q38306767-9D910C5C-E4FC-4698-AFC2-C1032EC84F47Q38800853-DDCB7B11-2EDF-4F86-8083-3D140A2CD9F0Q38817144-BEFBDA6A-6B55-490C-8C18-7A1013AC1F72Q38844348-1CDA4DBC-59B6-4B39-B41D-B0009376EBD5Q39635786-D03A6097-AAB0-42B9-ADF9-694D4AAF475C
P2860
Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@ast
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@en
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@nl
type
label
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@ast
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@en
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@nl
prefLabel
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@ast
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@en
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@nl
P2093
P50
P921
P356
P1476
Clopidogrel non-responsiveness ...... ity. An updated meta-analysis.
@en
P2093
Anna Maria Gori
Gian Franco Gensini
Rosanna Abbate
P304
P356
10.1160/TH09-06-0418
P577
2010-02-02T00:00:00Z